The use of phage-displayed peptide libraries to develop tumor-targeting drugs

被引:69
作者
Krumpe, LRH
Mori, T
机构
[1] Takeda Pharmaceut Co Ltd, Biomed Res Labs, Div Pharmaceut Res, Osaka 5328686, Japan
[2] Sci Applicat Int Corp Frederick Inc, Basic Res Program, Frederick, MD USA
[3] Natl Canc Inst, Mol Targets Dev Program, Canc Res Ctr, Frederick, MD USA
关键词
phage display; peptide; library; tumor; cancer; targeting; homing; drug; imaging; nanotechnology; biopanning; T7; M; 13; lytic phage; filamentous phage;
D O I
10.1007/s10989-005-9002-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Monoclonal antibodies have been successfully utilized as cancer-targeting therapeutics and diagnostics, but the efficacies of these treatments are limited in part by the size of the molecules and non-specific uptake by the reticuloendothelial system. Peptides are much smaller molecules that can specifically target cancer cells and as such may alleviate complications with antibody therapy. Although many endogenous and exogenous peptides have been developed into clinical therapeutics, only a subset of these consists of cancer-targeting peptides. Combinatorial biological libraries such as bacteriophage-displayed peptide libraries are a resource of potential ligands for various cancer-related molecular targets. Target-binding peptides can be affinity selected from complex mixtures of billions of displayed peptides on phage and further enriched through the biopanning process. Various cancer-specific ligands have been isolated by in vitro, in vivo, and ex vivo screening methods. As several peptides derived from phage-displayed peptide library screenings have been developed into therapeutics in current clinical trials, which validates peptide-targeting potential, the use of phage display to identify cancer-targeting therapeutics should be further exploited.
引用
收藏
页码:79 / 91
页数:13
相关论文
共 90 条
[1]  
Adams GP, 2001, CANCER RES, V61, P4750
[2]   Monoclonal antibody therapy of cancer [J].
Adams, GP ;
Weiner, LM .
NATURE BIOTECHNOLOGY, 2005, 23 (09) :1147-1157
[3]   Exploiting natural peptide diversity:: novel research tools and drug leads [J].
Adermann, K ;
John, H ;
Ständker, L ;
Forssmann, WG .
CURRENT OPINION IN BIOTECHNOLOGY, 2004, 15 (06) :599-606
[4]   Converting a peptide into a drug: Strategies to improve stability and bioavailability [J].
Adessi, C ;
Soto, C .
CURRENT MEDICINAL CHEMISTRY, 2002, 9 (09) :963-978
[5]   Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries [J].
Aina, OH ;
Marik, J ;
Liu, RW ;
Lau, DH ;
Lam, KS .
MOLECULAR CANCER THERAPEUTICS, 2005, 4 (05) :806-813
[6]   Therapeutic cancer targeting peptides [J].
Aina, OH ;
Sroka, TC ;
Chen, ML ;
Lam, KS .
BIOPOLYMERS, 2002, 66 (03) :184-199
[7]   Nanocrystal targeting in vivo [J].
Åkerman, ME ;
Chan, WCW ;
Laakkonen, P ;
Bhatia, SN ;
Ruoslahti, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (20) :12617-12621
[8]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[9]   Steps toward mapping the human vasculature by phage display [J].
Arap, W ;
Kolonin, MG ;
Trepel, M ;
Lahdenranta, J ;
Cardó-Vila, M ;
Giordano, RJ ;
Mintz, PJ ;
Ardelt, PU ;
Yao, VJ ;
Vidal, CI ;
Chen, L ;
Flamm, A ;
Valtanen, H ;
Weavind, LM ;
Hicks, ME ;
Pollock, RE ;
Botz, GH ;
Bucana, CD ;
Koivunen, E ;
Cahill, D ;
Troncoso, P ;
Baggerly, KA ;
Pentz, RD ;
Do, KA ;
Logothetis, CJ ;
Pasqualini, R .
NATURE MEDICINE, 2002, 8 (02) :121-127
[10]   Targeting the prostate for destruction through a vascular address [J].
Arap, W ;
Haedicke, W ;
Bernasconi, M ;
Kain, R ;
Rajotte, D ;
Krajewski, S ;
Ellerby, HM ;
Bredesen, DE ;
Pasqualini, R ;
Ruoslahti, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (03) :1527-1531